Trastuzumab-associated cardiac events in the Persephone trial

Ítems similars

• Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results
  per: Hiller, Louise, et al.
  Publicat: (2018)
• Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
  per: Helena Earl, et al.
  Publicat: (2020-08-01)
• Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
  per: Earl, Helena, et al.
  Publicat: (2020)
• 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
  per: Earl, Helena M, et al.
  Publicat: (2019)
• Optimising patient recall of adverse events over prolonged time periods
  per: Hiller, Louise, et al.
  Publicat: (2011)